Meanwhile, a recent study showed that Gleevec, a well-known anticancer drug that exhibits dramatic effectiveness for the treatment of chronic myelocytic leukemia and gastrointestinal stromal tumors (52), also blocks the CDK5-mediated PPARγ S273 phosphorylation and improves insulin sensitivity without classical PPARγ agonism and related side effects. The gene discussed is CDK5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.